Clinical Trial Update: Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease [Phase 3]

View source ↗

Summary

This open-label extension of pegunigalsidase alfa at 1 mg/kg every 2 weeks in Fabry disease has completed Phase 3, and results were posted on 2026-03-24.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Pegunigalsidase alfa (pegunigalsidase alfa)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Fabry Disease | Phase 3 | Status: COMPLETED | Results posted: 2026-03-24